Detalhe da pesquisa
1.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
2.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood
; 135(15): 1204-1213, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876911
3.
Discovery of quinoline-based irreversible BTK inhibitors.
Bioorg Med Chem Lett
; 30(14): 127261, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32527559
4.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241979
5.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 323-32, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26641137
6.
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
J Pharmacol Exp Ther
; 363(2): 240-252, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882879
7.
Single cell network profiling assay in bladder cancer.
Cytometry A
; 83(4): 386-95, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23300058
8.
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Clin Cancer Res
; 26(12): 2800-2809, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32054731
9.
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Clin Cancer Res
; 23(19): 5814-5823, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28645939
10.
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 23(11): 2831-2841, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903679
11.
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
PLoS One
; 11(7): e0159607, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27434128
12.
The role of the DNA damage response in zebrafish and cellular models of Diamond Blackfan anemia.
Dis Model Mech
; 7(7): 895-905, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24812435
13.
Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.
Best Pract Res Clin Haematol
; 23(3): 319-31, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21112033
14.
Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease.
Autoimmunity
; 43(7): 550-9, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20482423
15.
Single cell network profiling (SCNP): mapping drug and target interactions.
Assay Drug Dev Technol
; 8(3): 321-43, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20158439
16.
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
Clin Cancer Res
; 16(14): 3721-33, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525753
17.
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.
PLoS One
; 5(8): e12405, 2010 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-20811632
18.
Embryonal subregion-derived stromal cell lines from novel temperature-sensitive SV40 T antigen transgenic mice support hematopoiesis.
J Cell Sci
; 115(Pt 10): 2099-108, 2002 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11973351
19.
The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity.
J Immunol
; 173(9): 5626-34, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15494513